An interventional study of Transcatheter Mitral Valve Replacement in Mitral Valve Disease, sponsored by Mayra Guerrero. Completed at 15 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2023-10-10.
Sponsored by Mayra Guerrero · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this trial is to establish the safety and feasibility of the Edwards SAPIEN XT™and SAPIEN 3™ device and delivery systems in patients with severe symptomatic calcific mitral valve disease with severe mitral annular calcification who are not candidates for standard mitral valve surgery.
Design:
A prospective pilot study enrolling extremely high surgical risk patients with symptomatic severe calcific mitral valve disease undergoing implantation of an Edwards Sapien XT or SAPIEN 3 valve in the mitral position.
There are three arms in this study evaluating three separate patient populations described below:
The delivery approaches include: standard transeptal, modified transeptal approach with a guidewire externalized through a sheath percutaneously placed in the left ventricle, surgical trasnapical and surgical transatrial delivery approach with or without surgical resection of the anterior mitral valve (MV) leaflet (in the native mitral valve arm).
The MITRAL Trial site investigative team (heart team) consists of dedicated representatives from cardiac surgery, interventional cardiology, echocardiology, neurology, study coordination and other multi-disciplinary team members consistent with a transcatheter aortic valve replacement (TAVR) model.
Endpoints
Most endpoints were defined following the Mitral Valve Academic Research Consortium (MVARC) recommendations with minor modifications.73
The primary safety endpoint is: technical success at exit from the cath lab
The primary performance endpoint is: absence of MR grade 2 (+) or greater or mean MVG ≥10 mmHg at 30 days and 1 year.
Secondary safety endpoints include: Procedural success and all -cause mortality at 30 days and 1 year.
Procedural Success (30 days) in defined as:
Device success is defined as:
Additional secondary safety and effectiveness endpoints will be evaluated at two time points: (1) acute, covering events occurring out to 30 days or hospital discharge, whichever is longer; and (2) longer-term, covering events from 31 days to 1 year, and include the following:
Additional Safety Endpoints:
Freedom from
Additional Effectiveness Endpoints:
Additional Valve Performance Endpoints:
Mayra Guerrero is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria in Native Mitral Valve arm
All Candidates must meet the following criteria:
Inclusion Criteria in Valve-in-Ring arm
All Candidates must meet the following criteria:
Inclusion Criteria items #3 to 7 will be the same as in Native MV arm described above
Inclusion Criteria in Valve-in-Valve arm
All Candidates must meet the following criteria:
Inclusion Criteria items #3 to 7 will be the same as in Native MV arm described above
Exclusion Criteria:
Candidates will be excluded from the study if any of the following conditions are present:
Complex untreated coronary artery disease:
For patients enrolled in the Native MV arm: Native mitral annulus size \< 275 mm2 or > 740 mm2 as measured by CT scan.
For patients in Valve-in-Ring arm: surgical ring with a true mean internal diameter ≤18 mm or ≥ 29 mm or an area \< 275 mm2 or > 740 mm2 as measured by CT scan. Caution recommended in:
For patients in Valve-in-Valve arm: surgical bioprosthesis with a true internal diameter ≤18 mm or ≥ 29 mm
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.
Device: Transcatheter Mitral Valve Replacement
Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).
Device: Transcatheter Mitral Valve Replacement
Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).
Device: Transcatheter Mitral Valve Replacement
Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
Technical Success at Exit From the Cath Lab.
Number of subject to achieve technical success (at exit from cath lab) is defined as: * Successful vascular delivery and retrieval of transcatheter valve delivery system * Deployment of single valve * Correct position of transcatheter valve * Adequate performance of prosthesis (MVA \> 1.5 cm2) without residual MR grade ≥2 (+) * No need for additional surgery or re-intervention * Patient leaves cath lab alive
Time frame: 30 days
Absence of MR Grade 2 (+) or Greater
Number of subjects to have absence of MR grade 2 (+) or greater assessed with echocardiography. MR severity grading system ranging from Grade 1=mild; Grade 4=severe.
Time frame: 30 days and 1 year
Mitral Valve Gradient (MVG)
MVG assessed by echocardiography measured in mmHg
Time frame: 30 days and 1 year
Procedural Success
Number of subject to have procedural success as defined as no device/procedure related SAE's including: death, stroke, MI or coronary ischemia requiring PCI or CABG, stage 2 or 3 AKI including dialysis, life threatening bleeding, major vascular or access complications (arterial, venous, or TA - any event requiring additional unplanned surgical or transcatheter intervention), pericardial effusion or tamponade requiring drainage, severe hypotension, heart failure or respiratory failure requiring intravenous pressors or invasive or mechanical treatments such as ultrafiltration or hemodynamic assist devices including intra-aortic balloon pump or left ventricular assist device, or prolonged intubation for ≥48 hrs, or any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention.
Time frame: 30 days
| Milestone | Native Mitral Valve With Severe MAC | Valve-in-Ring | Valve-in-Valve |
|---|---|---|---|
| Started | 31 | 30 | 30 |
| Completed | 19 | 19 | 29 |
| Not completed | 12 | 11 | 1 |
| Withdrew: Death | 10 | 7 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 4 | 0 |
Number of subject to achieve technical success (at exit from cath lab) is defined as: * Successful vascular delivery and retrieval of transcatheter valve delivery system * Deployment of single valve * Correct position of transcatheter valve * Adequate performance of prosthesis (MVA \> 1.5 cm2) without residual MR grade ≥2 (+) * No need for additional surgery or re-intervention * Patient leaves cath lab alive
| Participants | Native Mitral Valve With Severe MAC | Valve-in-Ring | Valve-in-Valve |
|---|---|---|---|
| Technical Success at Exit From the Cath Lab. | 23 | 20 | 30 |
Number of subjects to have absence of MR grade 2 (+) or greater assessed with echocardiography. MR severity grading system ranging from Grade 1=mild; Grade 4=severe.
| Participants | Native Mitral Valve With Severe MAC | Valve-in-Ring | Valve-in-Valve |
|---|---|---|---|
| 30 days | 23 | 28 | 29 |
| 1 year | 18 | 19 | 29 |
MVG assessed by echocardiography measured in mmHg
| mmHg | Native Mitral Valve With Severe MAC | Valve-in-Ring | Valve-in-Valve |
|---|---|---|---|
| 30 days | 6.0 (5.2 to 7.8) | 7.6 (5.9 to 9.1) | 6.0 (4.7 to 7.3) |
| 1 year | 6.1 (5.6 to 7.1) | 6.0 (4.7 to 7.3) | 6.6 (5.5 to 8.9) |
Number of subject to have procedural success as defined as no device/procedure related SAE's including: death, stroke, MI or coronary ischemia requiring PCI or CABG, stage 2 or 3 AKI including dialysis, life threatening bleeding, major vascular or access complications (arterial, venous, or TA - any event requiring additional unplanned surgical or transcatheter intervention), pericardial effusion or tamponade requiring drainage, severe hypotension, heart failure or respiratory failure requiring intravenous pressors or invasive or mechanical treatments such as ultrafiltration or hemodynamic assist devices including intra-aortic balloon pump or left ventricular assist device, or prolonged intubation for ≥48 hrs, or any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention.
| Participants | Native Mitral Valve With Severe MAC | Valve-in-Ring | Valve-in-Valve |
|---|---|---|---|
| Procedural Success | 16 | 22 | 28 |
Collected over Adverse events were collected all subjects from baseline to end of study, approximately one year.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Native Mitral Valve With Severe MAC | 10/31 (32.3%) | 18/31 (58.1%) | 17/31 (54.8%) |
| Valve-in-Ring | 7/30 (23.3%) | 13/30 (43.3%) | 12/30 (40%) |
| Valve-in-Valve | 1/30 (3.3%) | 8/30 (26.7%) | 6/30 (20%) |
| Event | Native Mitral Valve With Severe MAC | Valve-in-Ring | Valve-in-Valve |
|---|---|---|---|
| New rehospitalization for heart failureCardiac disorders | 11/31 | 5/30 | 5/30 |
| Acute Kidney InjuryRenal and urinary disorders | 5/31 | 4/30 | 0/30 |
| Atrial fibrillationCardiac disorders | 5/31 | 1/30 | 0/30 |
| Hemolytic anemiaBlood and lymphatic system disorders | 5/31 | 3/30 | 0/30 |
| New permanent pacemaker requirementCardiac disorders | 5/31 | 0/30 | 1/30 |
| Mitral valve reintervention after index procedureCardiac disorders | 4/31 | 3/30 | 0/30 |
| StrokeNervous system disorders | 2/31 | 1/30 | 2/30 |
| Vascular complicationsVascular disorders | 1/31 | 2/30 | 1/30 |
| Valve thrombosisVascular disorders | 1/31 | 0/30 | 0/30 |
| Event | Native Mitral Valve With Severe MAC | Valve-in-Ring | Valve-in-Valve |
|---|---|---|---|
| Blood transfusionBlood and lymphatic system disorders | 17/31 | 12/30 | 6/30 |
| Age, Continuous(years) | Native Mitral Valve With Severe MAC | Valve-in-Ring | Valve-in-Valve | Total |
|---|---|---|---|---|
| Median | 74.5 (71.3 to 81.0) | 71.5 (67.0 to 76.8) | 77.5 (70.3 to 82.8) | 75.5 (67.75 to 82.25) |
| Sex: Female, Male(Participants) | Native Mitral Valve With Severe MAC | Valve-in-Ring | Valve-in-Valve | Total |
|---|---|---|---|---|
| Female | 22 | 11 | 19 | 52 |
| Male | 9 | 19 | 11 | 39 |
| Ethnicity (NIH/OMB)(Participants) | Native Mitral Valve With Severe MAC | Valve-in-Ring | Valve-in-Valve | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 0 | 3 |
| Not Hispanic or Latino | 30 | 28 | 30 | 88 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Native Mitral Valve With Severe MAC | Valve-in-Ring | Valve-in-Valve | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 4 | 6 |
| White | 31 | 27 | 25 | 83 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Native Mitral Valve With Severe MAC | Valve-in-Ring | Valve-in-Valve | Total |
|---|---|---|---|---|
| United States | 31 | 30 | 30 | 91 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2015 to primary completion in Dec 2018, 46 months.
Results were first posted in Aug 2021, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mayra Guerrero